Descriptor: "OVERALL survival" / Database: Academic Search Index / Language: english / Publication Year Range: This year / Publisher: mjh life sciences - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"OVERALL survival"' showing total 7 results

Start Over Descriptor "OVERALL survival" Publication Year Range This year Language english Database Academic Search Index Publisher mjh life sciences

Author: RYAN, CHRIS
Subjects: *BLADDER cancer treatment, *CIRCULATING tumor DNA, *NEOADJUVANT chemotherapy, *OVERALL survival, *PROGRESSION-free survival
Published: 2024

Author: CLARKE, HANNAH and HOLLASCH, MEGAN
Subjects: *THERAPEUTIC use of monoclonal antibodies, *RISK assessment, *PLACEBOS, *DEATH, *CANCER relapse, *DRUG side effects, *PATIENT safety, *CLINICAL trials, *TERMINATION of treatment, *NEPHRECTOMY, *RENAL cell carcinoma, *DISEASE relapse, *PROGRESSION-free survival, *TUMOR classification, *OVERALL survival, *PATIENT aftercare, *EVALUATION, *DISEASE risk factors
Abstract: The article discusses updated data as of 2024 which shows that adjuvant pembrolizumab (Keytruda) extended overall survival (OS) in patients with clear cell renal cell carcinoma (ccRCC) at medium or high risk of recurrence. It states that the therapy improved disease-free survival (DFS) and lowered distant and local disease recurrence. Also noted are the occurrences of immune-mediated adverse events (AE) and infusion reactions among patients.
Published: 2024

Author: Cookson, Michael S.
Subjects: *NON-muscle invasive bladder cancer, *GENE therapy, *UROLOGY, *BCG vaccines, *IMMUNOTHERAPY, *ANTINEOPLASTIC agents, *DISEASE management, *TREATMENT effectiveness, *SEVERITY of illness index, *IMMUNE checkpoint inhibitors, *OVERALL survival, BLADDER tumors
Abstract: The article highlights advancements in the treatment of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). These include nadofaragene firadenovec intravesical gene therapy, pembrolizumab systemic therapy, TAR-200 drug intravesical delivery system using gemcitabine and gemcitabine plus a PD-L1 inhibitor, combination chemotherapy with gemcitabine and docetaxel, and QUILT-3.032 study on the synergy between immune checkpoint inhibitors and targeted therapies.
Published: 2024

Author: SAYLOR, BENJAMIN P.
Subjects: *THERAPEUTIC use of antineoplastic agents, *DOCETAXEL, *ANTIANDROGENS, *CASTRATION-resistant prostate cancer, *PLACEBOS, *PROSTATE tumors, *TREATMENT effectiveness, *METASTASIS, *DISEASE progression, *OVERALL survival
Abstract: The article focuses on the results of the phase three ARASENS trial on the effectiveness of darolutamide as a treatment in patients with metastatic hormone-sensitive prostate cancer, which were presented at the 2024 American Society of Clinical Oncology Annual Meeting held in Chicago, Illinois. Topics discussed include the improvementin the overall survival and delay time to progression to metastatic castration-resistant disease, and the definition of postprogression survival.
Published: 2024

Author: CLARKE, HANNAH
Subjects: *THERAPEUTIC use of antineoplastic agents, *PROSTATE tumors, *EVALUATION of medical care, *CANCER patients, *METASTASIS, *HORMONE therapy, *OVERALL survival, *TIME, *COMORBIDITY
Abstract: The article focuses on a study which shows an improvement in the overall survival (OS) among patients with de novo metastatic hormone-sensitive prostate cancer in clinical practice in the U.S. from 2000 to 2019, which references a research paper by Martin Schoen et al., published in an issue of the "JAMA Network Open." Topics discussed include the median OS in patients younger than 70 years, and the significant role of combination therapy in this improvement.
Published: 2024

Author: CLARKE, HANNAH
Subjects: *PREVENTION of drug side effects, *THERAPEUTIC use of monoclonal antibodies, *CANCER relapse, *PATIENT safety, *INVESTIGATIONAL drugs, *TERMINATION of treatment, *CLINICAL trials, *CANCER chemotherapy, *METASTASIS, *DRUG approval, *ENDOMETRIAL tumors, *COMBINED modality therapy, *DRUG efficacy, *PROGRESSION-free survival, *LUNG cancer, *OVERALL survival, *DISEASE progression, *HEPATOCELLULAR carcinoma, TUMOR surgery, BLADDER tumors, BILE duct tumors
Abstract: The article focuses on a news release from AstraZeneca on the results of the phase three NIAGARA trial, which shows the effectiveness of the combination of durvalumab and chemotherapy in improving event-free survival and overall survival in patients with muscle-invasive bladder cancer. Topics discussed include the safety of durvalumab in the trial, and the selection of the participants.
Published: 2024

Author: CLARKE, HANNAH
Subjects: *NON-muscle invasive bladder cancer, *CYSTOSCOPY, *EARLY detection of cancer, *DISEASE relapse, *PROGRESSION-free survival, *DISEASE progression, *OVERALL survival
Abstract: The article discusses 2024 data which showed that blue light cystoscopy (BLC) is linked to improved outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) compared to white light cystoscopy (WLC). Topics covered include the comparatively lower recurrence risk and progression risk for patients following BLC, and the latter's improved overall survival. Also noted is improved tumor visualization's help in determining intravesical therapy use, such as Bacillus Calmette-Guerin (BCG).
Published: 2024

Books, media, physical & digital resources

Searchworks